The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 424-431

  Wu, Y Jeffrey ^a   Muldoon, Leslie L ^a   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; APOPTOSIS INDUCING FACTOR; CASPASE; CELL CYCLE PROTEIN; CISPLATIN; DEATH RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 13244291452     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.075119     Document Type: Article

References (33)

1. Arany I, Megyesi JK, Kaneto H, Price PM, and Safirstein RL (2004) Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287:F543-F549.
2. Bennet MR (1999) Mechanisms of p53-induced apoptosis. Biochem Pharmacol 58:1089-1095.
3. Cregan SP, Dawson VL, and Slack RS (2004) Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 23:2785-2738.
4. Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, and Persons EL (2000) Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 29:219-228.
5. De Flora S, Izzotti A, D'Agostini F, and Balansky RM (2001) Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22:999-1013.
6. Del Bello B, Valentini MA, Mangiavacchi P, Comporti M, and Maellaro E (2004) Role of caspases-3 and -7 in Apaf-1 proteolytic cleavage and degradation events during cisplatin-induced apoptosis in melanoma cells. Exp Cell Res 293:302-310.
7. Dickey DT, Muldoon LL, Kraemer DF, and Neuwelt EA (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat mole. Hearing Res 193:25-30.
8. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, and Debatin KM (1998) Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ 5:884-893.
9. Hamers FP, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, and Gispen WH (1993) Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53:544-549.
10. Hashimoto S, Gon Y, Matsumoto K, Takeshita I, and Horie T (2001) N-Acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br J Pharmacol 132:270-276.
11. Jamieson ER and Lippard SJ (1999) Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
12. Jones NA, Turner J, McIlwrath AJ, Brown R, and Dive C (1998) Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 53:819-826.
13. Levin S, Buci TJ, Cohen SM, Fix AS, Hardisty JF, LeGrand EK, Maronpot RR, and Trump BJ (1999) The nomenclature of cell death: recommendations of an ad hoc Committee of the Society of Toxicologic Pathologists. Toxicol Pathol 27:484-490.
14. Li WQ, Dehnade F, and Zafarullah M (2000) Thiol antioxidant, N-acetylcysteine, activates extracellular signal-regulated kinase signaling pathway in articular chondrocytes. Biochem Biophys Res Commun 275:789-794.
15. Lincet H, Poulain L, Remy JS, Deslandes E, Duigou F, Gauduchon P, and Staedel C (2000) The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 161:17-26.
16. Losa JH, Cobo CP, Viniegra JG, Lobo VJSA, Cajal SR, and Sánchez-Prieto R (2003) Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22:3998-4006.
17. Mahyar-Roemer M and Roemer K (2001) p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20:3387-3398.
18. Masuda H, Tanaka T, and Takahama U (1994) Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 203:1175-1180.
19. Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ, and Neuwelt EA (2000) Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6:309-315.
20. Muldoon LL, Walker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC, and Neuwelt EA (2001) Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Ther 296:797-805.
21. Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, and Muldoon LL (2001) Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61:7868-7874.
22. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, and Muldoon LL (2004) Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309:594-599.
23. Nowak G, Price PM, and Schnellmann RG (2003) Lack of a functional p21WAF1/ CIP1 gene accelerates caspase-independent apoptosis induced by cisplatin in renal cells. Am J Physiol Renal Physiol 285:F440-F450.
24. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, and Green GR (2000) p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 275:7337-7342.
25. Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, and Tasaka K (2000) Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 45:199-206.
26. Shapiro GI and Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Investig 104:1645-1653.
27. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
28. Sun X-M, MacFarlane M, Zhuang J, Wolf BB, Green DR, and Cohen GM (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274:5053-5060.
29. Wada T and Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838-2849.
30. Wang X, Martindale JL, and Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435-39443.
31. Wung BS, Cheng JJ, Chao YJ, Hsieh HJ, and Wang DL (1999) Modulation of Ras/Raf/extracellular signal-regulated kinase pathway by reactive oxygen species is involved in cyclic strain-induced early growth response-1 gene expression in endothelial cells. Circ Res 84:804-812.
32. Zafarullah M, Li WQ, Sylvester J, and Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6-20.
33. Zhan Y, van de Water B, Wang Y, and Stevens JL (1999) The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene 18:6502-6512.